右美托咪定与危重症患者新发心房颤动的关联
该研究基于MIMIC-IV数据库2008至2019年Beth Israel Deaconess Medical Center的ICU患者记录,纳入18岁及以上ICU住院患者22237例,按ICU入院48小时内是否使用右美托咪定分为两组,行1:3倾向评分匹配后纳入8015例(右美托咪定组2106例、无右美托咪定组5909例)。主要终点为ICU入院7天内护士记录节律定义的新发房颤,右美托咪定组371例(17.6%)vs 无右美托咪定组1323例(22.4%),HR 0.80(95%CI 0.71-0.90)。右美托咪定组ICU住院时间与医院住院时间均更长(P<.001),但院内死亡风险更低(132例[6.3%] vs 758例[12.8%];HR 0.43,95%CI 0.36-0.52)。作者认为该关联可能有必要在 future 临床试验中评估。
要点
- 匹配后右美托咪定组新发房颤371例(17.6%)vs 无右美托咪定组1323例(22.4%),HR 0.80(95%CI 0.71-0.90)。
- 右美托咪定组院内死亡132例(6.3%)vs 无右美托咪定组758例(12.8%),HR 0.43(95%CI 0.36-0.52)。
- 右美托咪定组ICU住院时间中位数4.0天(IQR 2.7-6.9)vs 3.5天(IQR 2.5-5.9),P<.001。
- 右美托咪定组医院住院时间中位数10.0天(IQR 6.6-16.3)vs 8.8天(IQR 5.9-14.0),P<.001。
- 作者认为该关联可能有必要在 future 临床试验中评估。
适用人群与场景
- 年龄18岁及以上、入住ICU的患者,数据来自MIMIC-IV数据库2008至2019年Beth Israel Deaconess Medical Center的ICU记录。
- 暴露分组:ICU入院48小时内接受右美托咪定为右美托咪定组,从未接受右美托咪定为无右美托咪定组。
诊断标准与关键阈值
- 新发房颤定义为ICU入院7天内护士记录的节律状态。
研究设计与关键结果
- 研究类型:倾向评分匹配队列研究;匹配前22237例(平均[SD]年龄65.9[16.7]岁;男性12350例[55.5%]),1:3倾向评分匹配后8015例(平均[SD]年龄61.0[17.1]岁;男性5240例[65.4%]),右美托咪定组2106例、无右美托咪定组5909例。
- 主要终点:右美托咪定组新发房颤371例(17.6%)vs 无右美托咪定组1323例(22.4%),HR 0.80(95%CI 0.71-0.90)。
- 次要终点:右美托咪定组ICU住院时间中位数4.0天(IQR 2.7-6.9)vs 无右美托咪定组3.5天(IQR 2.5-5.9),P<.001;医院住院时间中位数10.0天(IQR 6.6-16.3)vs 8.8天(IQR 5.9-14.0),P<.001。
- 院内死亡:右美托咪定组132例(6.3%)vs 无右美托咪定组758例(12.8%),HR 0.43(95%CI 0.36-0.52)。
证据类型、等级与局限
- 证据类型:倾向评分匹配队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该关联可能有必要在 future 临床试验中评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Dexmedetomidine is a widely used sedative in the intensive care unit (ICU) and has unique properties that may be associated with reduced occurrence of new-onset atrial fibrillation (NOAF).
OBJECTIVE: To investigate whether the use of dexmedetomidine is associated with the incidence of NOAF in patients with critical illness.
DESIGN, SETTING, AND PARTICIPANTS: This propensity score-matched cohort study was conducted using the Medical Information Mart for Intensive Care-IV database, which includes records of patients admitted to the ICU at Beth Israel Deaconess Medical Center in Boston dating 2008 through 2019. Included patients were those aged 18 years or older and hospitalized in the ICU. Data were analyzed from March through May 2022.
EXPOSURE: Patients were divided into 2 groups according to dexmedetomidine exposure: those who received dexmedetomidine within 48 hours after ICU admission (dexmedetomidine group) and those who never received dexmedetomidine (no dexmedetomidine group).
MAIN OUTCOMES AND MEASURES: The primary outcome was the occurrence of NOAF within 7 days of ICU admission, as defined by the nurse-recorded rhythm status. Secondary outcomes were ICU length of stay, hospital length of stay, and in-hospital mortality.
RESULTS: This study included 22 237 patients before matching (mean [SD] age, 65.9 [16.7] years; 12 350 male patients [55.5%]). After 1:3 propensity score matching, the cohort included 8015 patients (mean [SD] age, 61.0 [17.1] years; 5240 males [65.4%]), among whom 2106 and 5909 patients were in the dexmedetomidine and no dexmedetomidine groups, respectively. Use of dexmedetomidine was associated with a decreased risk of NOAF (371 patients [17.6%] vs 1323 patients [22.4%]; hazard ratio, 0.80; 95% CI, 0.71-0.90). Although patients in the dexmedetomidine group had longer median (IQR) length of stays in the ICU (4.0 [2.7-6.9] days vs 3.5 [2.5-5.9] days; P < .001) and hospital (10.0 [6.6-16.3] days vs 8.8 [5.9-14.0] days; P < .001), dexmedetomidine was associated with decreased risk of in-hospital mortality (132 deaths [6.3%] vs 758 deaths [12.8%]; hazard ratio, 0.43; 95% CI, 0.36-0.52).
CONCLUSIONS AND RELEVANCE: This study found that dexmedetomidine was associated with decreased risk of NOAF in patients with critical illness, suggesting that it may be necessary and warranted to evaluate this association in future clinical trials.
参考来源
- Song MJ, Jang Y, Lee JH, et al. Association of Dexmedetomidine With New-Onset Atrial Fibrillation in Patients With Critical Illness. JAMA Netw Open. 2023. PMID: 37097632. doi:10.1001/jamanetworkopen.2023.9955
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。